-transparent.png){kind=logo}
Twenty otherwise health adults with a diagnosis of reversible obstructive airways disease were treated for one month in a single-blind crossover study with approximately equivalent doses of Elixophyllin SR capsules or Theo-Dur tablets. Both products provided evidence of efficacy by improvement in pulmonary function tests, and both were well tolerated. There were no significant differences between the two products with regard to bioavailability, efficacy, or tolerance. Both dosage forms appeared to have similar kinetic properties within the context of the study.
Related Publications
J J Trautlein, and
L Demers, and
V Esler, and
E Field
October 1987,
Journal of pharmaceutical sciences,
J J Trautlein, and
L Demers, and
V Esler, and
E Field
March 1986,
International journal of clinical pharmacology, therapy, and toxicology,
J J Trautlein, and
L Demers, and
V Esler, and
E Field
July 1984,
Journal of pharmaceutical sciences,
J J Trautlein, and
L Demers, and
V Esler, and
E Field
October 1974,
Clinical pharmacology and therapeutics,
J J Trautlein, and
L Demers, and
V Esler, and
E Field
January 1989,
Pharmaceutica acta Helvetiae,
J J Trautlein, and
L Demers, and
V Esler, and
E Field
April 1980,
Annals of allergy,
J J Trautlein, and
L Demers, and
V Esler, and
E Field
July 1986,
American journal of diseases of children (1960),
J J Trautlein, and
L Demers, and
V Esler, and
E Field
June 1975,
The New England journal of medicine,
J J Trautlein, and
L Demers, and
V Esler, and
E Field
April 1986,
International journal of clinical pharmacology, therapy, and toxicology,
J J Trautlein, and
L Demers, and
V Esler, and
E Field
May 1983,
International journal of clinical pharmacology, therapy, and toxicology,
